{"filing":{"accession_number":"0001493152-26-039109","cik":"0001595353","ticker":"GLMD","company_name":"Galmed Pharmaceuticals Ltd.","form":"6-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595353/000149315226039109/form6-k.htm"},"events":[{"id":28386,"run_id":25961,"accession_number":"0001493152-26-039109","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This exhibit announces successful completion of a first-in-human feasibility study for Colospan's novel intraoperative tissue assessment technology platform. The disclosure describes a clinical milestone—enrollment of 32 colorectal cancer patients, successful demonstration of technical feasibility, and establishment of a clinical foundation for continued development. This is a material operational/strategic milestone for a medical device company expanding its product pipeline beyond its lead product (CG-100), supporting Galmed's strategy to build a diversified portfolio in colorectal surgery. While not a discrete event type like M\u0026A or exec change, it represents a significant clinical and operational achievement that would affect a reasonable investor's assessment of the company's pipeline and strategic execution.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-08-19","form":"6-K","submitted_at":null,"items":[{"id":30316,"accession_number":"0001493152-26-039109","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit announces successful completion of a first-in-human feasibility study for Colospan's novel intraoperative tissue assessment technology platform. The disclosure describes a clinical milestone—enrollment of 32 colorectal cancer patients, successful demonstration of technical feasibility, and establishment of a clinical foundation for continued development. This is a material operational/strategic milestone for a medical device company expanding its product pipeline beyond its lead product (CG-100), supporting Galmed's strategy to build a diversified portfolio in colorectal surgery. While not a discrete event type like M\u0026A or exec change, it represents a significant clinical and operational achievement that would affect a reasonable investor's assessment of the company's pipeline and strategic execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:06:38.304840+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30316,"accession_number":"0001493152-26-039109","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit announces successful completion of a first-in-human feasibility study for Colospan's novel intraoperative tissue assessment technology platform. The disclosure describes a clinical milestone—enrollment of 32 colorectal cancer patients, successful demonstration of technical feasibility, and establishment of a clinical foundation for continued development. This is a material operational/strategic milestone for a medical device company expanding its product pipeline beyond its lead product (CG-100), supporting Galmed's strategy to build a diversified portfolio in colorectal surgery. While not a discrete event type like M\u0026A or exec change, it represents a significant clinical and operational achievement that would affect a reasonable investor's assessment of the company's pipeline and strategic execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:06:38.304840+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-08-19"}]}